Amneal launches 1st generic of Intelence
Intelence had a U.S. market size of roughly $99.4 million for the year ended April 2021, according to IQVIA data.
Amneal Pharmaceutical is introducing its generic Intelence (etravirine tablets) in two dosage strengths. The generic, approved by the Food and Drug Administration on June 14, will be sold in 100- and 200-mg dosage strengths.
Amneal’s generic is the first for Intelence and, like the reference drug, is indicated to treat HIV-1 in patients 6 years old and older who have received prior treatment for the condition.
The company will be offering the 100-mg dosage strength in 120-count bottles and the 200-mg dosage strength in 60-count bottles.
Intelence had a U.S. market size of roughly $99.4 million for the year ended April 2021, according to IQVIA data.